Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA91 in Relapsed/Refractory Autoimmune Diseases
NCT06970951Phase 1Not yet recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA91 in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome and 5 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Incidence and severity of Adverse Events at 1 year. Planned start May 2025; status: not yet recruiting.
02
Drugs
UTAA91
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)Sjögren's syndromeidiopathic inflammatory myopathies (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06970951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970951.